Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 33
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 33

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderArvinas · 29
Strongest available pathWAVE Life Sciences · +1.4%
Widest latest marginUltragenyx · -85.4%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ARVN · Nasdaq

Arvinas

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2013New Haven, Connecticut$606.8M market cap
View full Companies Radar profile
29Avoid
Snapshot price$9.28as of page date
Monthly-close return-88.7%five-year window
FY2021 revenue$0.05BARVINAS, INC.
Net margin-409.0%FY2021
P/E snapshot35.7xone ratio, not a verdict
Prism attention25.5%share across these five
Filing track recordRevenue, USD billions
+226.6%
$0$0.0B$0.0B$0.0BFY2018: $0.014BFY2019: $0.018BFY2020: $0.022BFY2021: $0.047B2018201920202021
FY2018–FY2021 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 48.4%
52-week position31% through range
$6.97$14.51
News mentions1.6K
Community mentions23partial coverage
U.S.-scope patents888
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal21/100
Management stability90/100
Market position0/100
Capital-event signal35/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2RARE · Nasdaq

Ultragenyx

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Novato, California$2.54B market cap
View full Companies Radar profile
29Avoid
Snapshot price$25.81as of page date
Monthly-close return-71.4%five-year window
FY2025 revenue$0.67BUltragenyx Pharmaceutical Inc.
Net margin-85.4%FY2025
P/E snapshot38.8xone ratio, not a verdict
Prism attention37.2%share across these five
Filing track recordRevenue, USD billions
+91.5%
$0$0.2B$0.4B$0.7BFY2021: $0.351BFY2022: $0.363BFY2023: $0.434BFY2024: $0.560BFY2025: $0.673B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.6%
52-week position35% through range
$18.29$39.89
News mentions2.4K
Community mentions26partial coverage
U.S.-scope patents479
Prism Insights

What sits behind the readiness signal

Observed risk 19/100higher means more observed risk
Earnings signal38/100
Management stability90/100
Market position9/100
Capital-event signal34/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 2 regulatory and 1 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3GOSS · Nasdaq

Gossamer Bio

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2017WILMINGTON$81.8M market cap
View full Companies Radar profile
28Avoid
Snapshot price$0.17as of page date
Monthly-close return-98.7%five-year window
FY2025 revenue$0.05BGossamer Bio, Inc.
Net margin-351.5%FY2025
P/E snapshot-0.9xone ratio, not a verdict
Prism attention12.2%share across these five
Filing track recordRevenue, USD billions
-57.7%
$0$0.0B$0.1B$0.1BFY2024: $0.115BFY2025: $0.048B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -57.7%
52-week position2% through range
$0.11$3.87
News mentions782
Community mentions10partial coverage
U.S.-scope patents23
Prism Insights

What sits behind the readiness signal

Observed risk 17/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position0/100
Capital-event signal47/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 1 regulatory and 1 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4WVE · Nasdaq

WAVE Life Sciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2012Boston$979.3M market cap
View full Companies Radar profile
28Avoid
Snapshot price$4.97as of page date
Monthly-close return+1.4%five-year window
FY2025 revenue$0.04BWave Life Sciences Ltd.
Net margin-478.3%FY2025
P/E snapshot-4.2xone ratio, not a verdict
Prism attention19.5%share across these five
Filing track recordRevenue, USD billions
+4.3%
$0$0.0B$0.1B$0.1BFY2021: $0.041BFY2022: $0.004BFY2023: $0.113BFY2024: $0.108BFY2025: $0.043B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.1%
52-week position1% through range
$4.80$21.73
News mentions1.3K
Community mentions24partial coverage
U.S.-scope patents128
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal20/100
Management stability90/100
Market position0/100
Capital-event signal30/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5KTTA · Nasdaq

Pasithea

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2020Miami Beach, Florida$18.8M market cap
View full Companies Radar profile
27Avoid
Snapshot price$0.56as of page date
Monthly-close return-99.1%five-year window
FY2022 revenue$0.00BPasithea Therapeutics Corp.
Net margin-2864.3%FY2022
P/E snapshot-1.2xone ratio, not a verdict
Prism attention5.6%share across these five
Filing track recordRevenue, USD billions
+3130.4%
$0$0.0B$0.0B$0.0BFY2021: $0.000BFY2022: $0.000B20212022
FY2021–FY2022 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 3130.4%
52-week position16% through range
$0.28$2.06
News mentions362
Community mentions0partial coverage
U.S.-scope patents15
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability70/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

WAVE Life Sciences
+1.4%
Ultragenyx
-71.4%
Arvinas
-88.7%
Gossamer Bio
-98.7%
Pasithea
-99.1%

Latest revenue

USD billions, official filing scope shown on each company card.

Ultragenyx
$0.67B
Gossamer Bio
$0.05B
Arvinas
$0.05B
WAVE Life Sciences
$0.04B
Pasithea
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Ultragenyx
-85.4%
Gossamer Bio
-351.5%
Arvinas
-409.0%
WAVE Life Sciences
-478.3%
Pasithea
-2864.3%

Prism news attention

Normalized share across these five names; attention is not quality.

Ultragenyx
37.2%
Arvinas
25.5%
WAVE Life Sciences
19.5%
Gossamer Bio
12.2%
Pasithea
5.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Ultragenyx leads the conversation

It holds 37.2% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.67B.

Price path

WAVE Life Sciences leads the available price paths

Its monthly-close return is +1.4% for the five-year window. At the other end, Pasithea is -99.1% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Ultragenyx has the widest latest margin

Its FY2025 net margin is -85.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

WAVE Life Sciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -4.2x while its five-year window price return is +1.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ARVN

Arvinas

1,642available Prism news records

Prism top themes

Price action & investor response
135
Earnings & financial performance
60
Legal, arbitration & regulatory
49
Leadership & governance
39
Capital allocation & transactions
34

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-15.2%336 latest 12m vs 396 prior 12m
2024-01: 9 mentions2024-02: 43 mentions2024-03: 13 mentions2024-04: 32 mentions2024-05: 27 mentions2024-06: 27 mentions2024-07: 28 mentions2024-08: 11 mentions2024-09: 6 mentions2024-10: 27 mentions2024-11: 17 mentions2024-12: 31 mentions2025-01: 24 mentions2025-02: 82 mentions2025-03: 46 mentions2025-04: 40 mentions2025-05: 39 mentions2025-06: 45 mentions2025-07: 9 mentions2025-08: 24 mentions2025-09: 52 mentions2025-10: 28 mentions2025-11: 24 mentions2025-12: 17 mentions2026-01: 17 mentions2026-02: 27 mentions2026-03: 23 mentions2026-04: 19 mentions2026-05: 89 mentions2026-06: 7 mentions2024-012026-06

Machine-classified coverage tone

87.9% positive+3.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 71stock performance 52cancer biomarkers 48neoadjuvant therapy breast cancer 39parp inhibitors breast cancer 38hormone therapy breast cancer 34adjuvant therapy breast cancer 33stock price 26

Keyword tag occurrences in available Prism news records.

Coverage: 2013-09-26–2026-06-12 · trend and themes shown through 2026-06
Areas of research · RARE

Ultragenyx

2,397available Prism news records

Prism top themes

Price action & investor response
84
Legal, arbitration & regulatory
53
Capital allocation & transactions
49
Earnings & financial performance
44
Leadership & governance
20

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+34.7%501 latest 12m vs 372 prior 12m
2024-01: 30 mentions2024-02: 55 mentions2024-03: 28 mentions2024-04: 44 mentions2024-05: 48 mentions2024-06: 44 mentions2024-07: 19 mentions2024-08: 25 mentions2024-09: 15 mentions2024-10: 16 mentions2024-11: 23 mentions2024-12: 14 mentions2025-01: 24 mentions2025-02: 118 mentions2025-03: 35 mentions2025-04: 24 mentions2025-05: 39 mentions2025-06: 20 mentions2025-07: 53 mentions2025-08: 26 mentions2025-09: 40 mentions2025-10: 17 mentions2025-11: 17 mentions2025-12: 38 mentions2026-01: 38 mentions2026-02: 103 mentions2026-03: 44 mentions2026-04: 65 mentions2026-05: 51 mentions2026-06: 9 mentions2024-012026-06

Machine-classified coverage tone

77.8% positive-11.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 202rare disease clinical trials 135rare disease treatment 130ultra-rare diseases 90orphan drug incentives 65orphan drug pricing 62rare disease registries 23orphan drug exclusivity 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-03–2026-06-18 · trend and themes shown through 2026-06
Areas of research · WVE

WAVE Life Sciences

1,253available Prism news records

Prism top themes

Price action & investor response
68
Legal, arbitration & regulatory
36
Earnings & financial performance
34
Capital allocation & transactions
29
Macro demand & rates
25

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+27.7%332 latest 12m vs 260 prior 12m
2024-01: 11 mentions2024-02: 11 mentions2024-03: 12 mentions2024-04: 12 mentions2024-05: 24 mentions2024-06: 26 mentions2024-07: 3 mentions2024-08: 17 mentions2024-09: 31 mentions2024-10: 44 mentions2024-11: 16 mentions2024-12: 8 mentions2025-01: 13 mentions2025-02: 47 mentions2025-03: 25 mentions2025-04: 26 mentions2025-05: 16 mentions2025-06: 14 mentions2025-07: 5 mentions2025-08: 14 mentions2025-09: 30 mentions2025-10: 16 mentions2025-11: 24 mentions2025-12: 59 mentions2026-01: 21 mentions2026-02: 51 mentions2026-03: 43 mentions2026-04: 45 mentions2026-05: 22 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

87.3% positive-4.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 37stock performance 20stock price 13crispr-cas9 11orphan drug pricing 10drug repurposing ai 9share price 9crispr applications 8

Keyword tag occurrences in available Prism news records.

Coverage: 2015-02-02–2026-06-13 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

RARE

Ultragenyx

26 mentions
Stock and valuation
13
Products, pricing and logistics
1
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 26 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ARVN

Arvinas

through 2026-04-03
Leadership changes 14Earnings releases 10Lawsuits 2Board updates 1Business contracts 1
  1. Earnings releases

    Gross Revenue $262.60 million 2.64 -$80.80 million ($1.28) -8.48

  2. Leadership changes

    Arvinas named Randy Teel, PhD as its president and CEO.

  3. Board updates

    At the annual meeting held on June 25, 2025, Arvinas Holding Company stockholders elected new Class I directors to the board

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RARE

Ultragenyx

through 2026-03-24
Earnings releases 33Company announcements 4Regulatory 2Lawsuits 1Leadership changes 1
  1. Lawsuits

    A deadline is coming up on April 6, 2026 in the lawsuit filed for certain investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) over alleged securities laws violations by Ultragenyx Pharmaceutical Inc.

  2. Earnings releases

    Total revenue for the year ended December 31, 2025 was $673 million, which represents 20% growth compared to the prior year, and a net loss of $575 million.

  3. Regulatory

    While reporting Breakthrough Therapy designation for GTX-102 in Angelman syndrome, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appears to be in a good position to advance UX143, which will be a transformational treatment for pediatric and adult patients with osteogenesis imperfecta.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GOSS

Gossamer Bio

through 2026-04-24
Earnings releases 11Regulatory 3Lawsuits 2Listing / IPO 1
  1. Lawsuits

    An investor, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), filed a lawsuit in the U.S. District Court for the Southern District of California over alleged violations of Federal Securities Laws by Gossamer Bio, Inc. in connection with certain allegedly false and misleading statements made between June 16, 2025, and February 20, 2026.

  2. Regulatory

    the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective December 5th, 2025, to a non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 200,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan.

  3. Earnings releases

    Cantor Fitzgerald also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.24) EPS.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

WVE

WAVE Life Sciences

through 2025-11-17
Company announcements 8Earnings releases 8Listing / IPO 4
  1. Earnings releases

    Wave Life Sciences Ltd. (NASDAQ:WVE) reported its Q3 results on November 10, 2025, where its $7.6 million revenue missed analyst forecasts of $12.89 million. At the same time, the company reduced its net loss from $61.8 million in Q3 2024 to $53.9 million, despite R&D and G&A expenses increasing to $45.9 million and $18.1 million.

  2. Listing / IPO

    Wave Life Sciences Pte. Ltd., of Singapore, set terms for an IPO in which it plans to sell 5 million shares, priced between $15 and $17 each. At its midpoint, the offering would gross $80 million.

  3. Company announcements

    Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KTTA

Pasithea

through 2023-03-30
Earnings releases 13
  1. Earnings releases

    Pasithea reported FY2022 revenue of $0.5M in the official-filing series.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 161–167. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Ultragenyx and Ultragenyx

Ultragenyx has the largest displayed latest revenue at $0.67B; Ultragenyx has the widest displayed latest margin at -85.4%.

Open Ultragenyx in Companies Radar
Comparisons
Anomalies

Ultragenyx has the widest attention-readiness rank gap

It ranks #1 by measured news attention (37.2%) and #2 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Ultragenyx in Companies Radar

Pasithea shows a price-operating divergence to inspect

Its displayed filing-revenue change is +3130.4% while its available monthly-close return is -99.1%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Pasithea in Companies Radar
Explanations

Attention measures coverage volume, not quality

Ultragenyx's 37.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Ultragenyx in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Arvinas's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 29/100 score.

Open Arvinas in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon